Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Isavuconazonium Sulfate IV via NG Tube vs Oral Capsules
NCT04096157Phase 1Completed
- Sponsor
- Astellas Pharma
- Start
- Sep 2019
- Primary completion
- Jan 2020
- Modality
- Prodrugs/Conditional Activator Small Molecules, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of isavuconazonium in invasive aspergillosis (IA) and mucormycosis (2 arms), sponsored by Astellas Pharma. Primary endpoints: Area under the concentration-time curve from the time of dosing extrapolated to time infinity at Day 21, Area under the concentration-time curve from 0 to 72 hours and 2 more. Started Sep 2019; status: completed.
02
Drugs
isavuconazonium
03
Conditions
invasive aspergillosis (IA)mucormycosis
Beyond the preview
Go deeper on NCT04096157.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04096157.